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Abstract Genetic Alzheimer’s disease (AD) accounts for
only few AD cases and is almost exclusively associated to
increased amyloid production in the brain. Instead, the
majority of patients is affected with the AD sporadic form
with typical alterations of clearance mechanisms of the
brain. Most studies use engineered animal models that
mimic genetic AD. Since it is emerging the existence of a
pathophysiological link between cardiovascular risk factors
and AD etiology, the strategy to develop animal models of
vascular related AD pathology could be the key toward
developing novel successful therapies. On this issue, we
have demonstrated that mice that have been chronically
subjected to high blood pressure show deposition of amy-
loid aggregates, the main histological feature of AD, and
loss of memory in specific tasks. More importantly, we
have identified that the hypertensive challenge increases
the expression of the receptor for advanced glycated end
products (RAGE), leading to beta-amyloid (Ab) deposition
and learning impairment. Here, we review different murine
models of hypertension, induced either pharmacologically
or mechanically, leading in the long time to plaque for-
mation in the brain parenchyma and around blood vessels.
The major findings obtained till now in this particular
experimental setting allow us to suggest that this appears to
be a unique possibility to study the pathogenetic mecha-
nisms of sporadic AD triggered by vascular risk factors.
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1 Introduction
Hypertension has a key role in brain pathologies, such as
stroke and dementia [1]. Lowering of elevated blood pres-
sure is clearly an important therapeutic target in the pre-
vention of stroke and, thus, of post stroke dementia [2].
Indeed, a single stroke can lead to dementia by interrupting
neural connections involved in cognition and memory. The
brain represents the main target organ of deleterious effects
caused by hypertension, responsible of a large portion of
related neurodegenerative disorders. Among these, Alzhei-
mer’s disease (AD) is considered the most common cause of
dementia in elderly. A growing body of epidemiological
studies have described that cardiovascular risk factors, such
as hypertension, increases the onset of AD [3–5]. While
early-onset/genetic AD accounts for only a small proportion
of total cases and is associated to an increased production of
the beta-amyloid (Ab) peptides, the majority of patients is
affected by late-onset/sporadic AD, due to a mechanism in
which the Ab clearance is altered. Both vascular efflux of Ab
across the blood-brain barrier (BBB) and/or influx of circu-
lating Ab in the central nervous system (CNS) are mecha-
nisms that, when dysregulated, may contribute to Ab
aggregation and its deposition in brain parenchyma [4–6].
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Chronic hypertension induces structural and functional
changes in cerebral blood vessels strongly affecting the
cerebral circulation. Recent findings have demonstrated that
hypertension triggers hypoperfusion due to impairment of
endothelial function that significantly modifies vascular
compliance [1–7].
Studies on genetic AD animal models further suggest an
interaction among anti-hypertensive therapies and a benefit
on cerebral amyloid pathology [8, 9]. However, the mecha-
nism underlying this relation seems to be complex. The
present review is aimed at providing novel insight into this
issue. First, we will examine the cerebrovascular alterations
induced by hypertension and then we will review the findings
in a unique animal model available until now to study
spontaneous AD, focusing on the AD-induced hypertension
and developed in our laboratory during the last years.
2 Vascular-Related Alzheimer Disease
How do vascular factors increase the risk of AD? Although
the answer to this question remains unclear, it represents one
of the oldest issues in understanding relationships between
AD and cerebrovascular diseases. The brain receives about
20 % of cardiac output and the fine crosstalk between neu-
rons and brain capillaries is critical for a proper brain
functioning [1]. Indeed, when the cerebral blood flow (CBF)
stops, neurons are damaged [10]. In AD the length reduction
of brain capillaries can lead to a diminished transport of
energy substrates and nutrients across the BBB [11, 12]. The
BBB is the brain endothelial structure specialized to sepa-
rate components of the circulating blood from neurons and
to maintain the chemical composition of the neuronal
microenvironment [6]. Within pericytes, astrocytes and
microglia, the BBB is required for preserving neuronal
circuits and synaptic transmission. Hemodynamic changes
caused by hypertension may disrupt the BBB, increasing the
vascular permeability and responsible for the accumulation
of Ab proteins in the cerebral parenchyma [13]. Soluble Ab
monomers precipitate and deposit around neurons, forming
insoluble and fibrillar aggregates [14, 15]. These complex
structures shape amyloid plaques characterizing AD [4] and
lead to neuronal death in the hippocampus and cortex,
responsible for cognitive decline and loss of memory [16].
Amyloid proteins have a different origin and their deposi-
tion in cerebral vasculature is still unknown; in fact, the
formation of aggregates depends on the different maturation
stage of peptides from monomeric to oligomeric forms, until
complex fibrillar structure, which are the agents responsible
of the early memory loss typical of AD [15, 17]. More
important, the number of fragments correlates with the
increase in blood pressure suggesting that pressure overload
further aggravates Ab deposition in the brain.
Studies in endothelial cell cultures have suggest that
peptides derived from APP (amyloid precursor protein)
produce deleterious vascular effects that may contribute to
neurodegeneration in AD. Since most cell types express
APP and could potentially release Ab, several mechanisms
can lead to a different parenchymal plaque formation. An
intriguing hypothesis poses that, the systemic mechanism
whereby Ab is transferred from blood to the vasculature,
could be related to the activation of RAGE, a major bidi-
rectional transporter of Ab across the BBB [18]. In trans-
genic models of AD, RAGE expression is increased in the
affected cerebral vessels, microglia and neurons. In addi-
tion to RAGE, apolipoprotein J (apoJ) can facilitate
transport of plasma-derived Ab across the BBB [19].
LRP-1 (low density lipoprotein-receptor-related protein-1)
mediates the opposite process, regulating the efflux from
brain to circulation and is localized at the apical face of
endothelium [20]. ApoE (apolipoprotein E), the most rel-
evant risk factor associated with AD, binds to LRP-1 to
modulating the rate of Ab transport [19]. The exchange of
Ab between CNS, CNF and blood is an important process
determining the concentration of Ab in the brain. On this
issue, the majority of patients affected by late-onset/spo-
radic AD may not have increased production of Ab [6], but
probably show a failure in the mechanisms responsible for
the clearance of Ab from the brain.
3 Murine Models of AD
Brain hypoperfusion and impaired BBB clearance of Ab
lead to accumulation of neurotoxic Ab oligomers in the
brain. Reduced blood flow and accumulated Ab oligomers
can both initiate the neuronal injury. For this reason, over
the last two decades, most attention has been focused on
genetic animal models that could resemble the AD patho-
logical features by overproducing the Ab, resulting in its
aggregation and deposition in brain parenchyma [21–24].
The disease phenotype includes the accumulation of Ab
and its deposition into senile plaques, the formation of tau
containing tangles, reactive gliosis, inflammation and an
immune response, neurodegeneration, cholinergic deficit,
and cognitive impairment [25].
Transgenic mice are the most popular animal models
for AD nowadays. The main reason behind this trend has
been the development and application of novel molecular
technologies, such as gene targeting, which enable
researcher to engineer precise genetic alteration to study
the neural basis of biochemical and behavioral alterations.
The genetically modified models usually include:
(i) Classical and conditional knockouts (KO). In the
classical model, the function of the investigated gene is
abolished from a very early stage of development,
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whereas, in conditional KO the gene inactivation is
restricted either to a specific time window or brain region.
(ii) Transgenics, in which a foreign gene is inserted into
the genome; (iii) Knock-in, in which specific mutations
are introduced in the gene leading to a loss of activity of
the proteins encoded by the targeted gene (although the
gene expression per se is not voided as it is in KOs).
Genetic causes of AD are heterogeneous and include
mutations or variants in several genes including the APP
gene, the presenilin (PS), and ApoE [26]. The first suc-
cessful genetically modified mouse models in AD
research were transgenics for Ab by increasing the load of
its precursor APP. In general, these lines develop robust
amyloid pathology and show cognitive impairment. From
a genetic point of view, all the genes encoding the sec-
retases that cleave the APP molecule can be considered
compelling candidate genes for AD. Especially interesting
are the b- and c-secretases, which catalyze the processing
of APP to the various Ab peptides [26], and a-secretase,
which is part of the non-amyloidogenic pathway [27].
ApoE mutation, which is strongest risk factor for AD,
have also been used to produce mouse models of AD. In
particular, the ApoE4 gene variant causes cognitive def-
icits whether expressed from astrocyte or in neuronal
promoters [28]. On this issue, mice knock-in for ApoE4
display impairment in cognitive and synaptic plasticity as
well as high plaque deposition when crossed with hAPP
mice [29]. In mouse models of AD, including APP-
overexpressing APPsw/0 mice and transgenic APP mice,
dense plaques develop initially on blood vessels or as a
classical CAA (cerebral amyloid angiopathy) [30]. It is
believed that plaques are generated on blood vessels due
to deficient Ab clearance across the BBB. Drugs that
downregulate RAGE and upregulate LRP at the BBB can
readjust the transport equilibrium for Ab by promoting its
efflux from brain into the bloodstream. In AD and in APP
transgenic models of AD, RAGE is significantly upregu-
lated at the BBB, whereas LRP is downregulated [30].
However, the mouse models described above mimic
genetic AD, constituting only a small fraction of total AD
cases. By contrast, our group has recently pursued the
strategy to develop the only animal model of hypertension-
related ‘Alzheimer-like’ pathology so far. In fact, we have
found that mice that have been subjected to chronic high
blood pressure showed accumulation of amyloid aggregates,
the main histological finding of AD, as well as other AD-
related features such as initiation of immune response, dys-
function of the BBB and cognitive impairment [31]. For a
long time, a clear association between AD and hypertension
has been reported, although the pathological link underlies
such association were not completely understood. Much
findings suggested that hypertension is an independent risk
factor for the incidence and progression of brain pathology.
4 Sporadic Versus Familial Alzheimer’s Disease
Alzheimer’s Disease is the leading cause of dementia in
elderly and, although some treatments help the symptoms
and slow the progression of the disease, no definitive cure
does exist. Early-onset/genetic AD accounts for only a small
proportion of total cases and is associated to an increased
production of the Ab-amyloid peptides. On the contrary, the
vast majority of patients is affected by late-onset/sporadic
AD, with no evident increase of Ab production, but probably
with a failure in the mechanisms responsible for clearance of
Ab from the brain. Both vascular efflux of Ab across BBB
and influx of circulating Ab in the CNS are mechanisms that,
when dysregulated, may contribute to Ab accumulation,
leading to its aggregation and deposition [4–6].
Actually, it seems that the only step forward for devel-
opment of novel rational therapies, is the identification of
factors influencing onset/progression of the sporadic AD.
Despite the old belief that AD, conversely to Vascular
Dementia, has a non-vascular origin, a growing body of
epidemiological studies strongly associate cardiovascular risk
factors, such as hypertension, to increased incidence of AD
[6]. Indeed, it is now well known that hypertension exerts a
strong impact on cerebral circulation, favoring hypoperfusion
through endothelial function impairment, increased smooth
muscle constrictor tone and structural remodeling that deeply
modifies vascular compliance [1–7]. Moreover, recent studies
on genetic AD animal models further suggest an interaction
among anti-hypertensive therapies and a benefit on cerebral
amyloid pathology and cognitive decline [8, 9]. However,
despite these clear links between hypertension and AD, few
basic science studies has investigated this relationship so far.
5 AD Induced by Hypertension: RAGE
Hypothesis
Many studies have focused on the possible mechanisms
underlying the cognitive impairment hypertension-induced,
but a pathophysiological link between hypertension and the
loss of memory in specific brain areas is still missing.
Cerebral blood vessels constitute the first line of defense
for the brain from the peripheral challenges, like hyper-
tension. Interestingly, RAGE receptor is expressed on
endothelial cells, and we found that hypertensive challenge
had an early effect of upregulation of RAGE expression in
cognitive brain areas [32]. Moreover, a recent study
examines the role of angiotensin II (AngII) type 1 receptor
system for RAGE expression in cultured endothelial cells
(ECs) from patients with essential hypertension [33]. AngII
up-regulated RAGE mRNA levels of microvascular ECs
and subsequently increased the expression of the soluble
form of RAGE (sRAGE) in the medium of ECs, suggesting
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that the renin-angiotensin system (RAS) contributes to the
development and progression of vascular angiopathy [33].
Chronic hypertension is associated with structural and
functional changes in cerebral blood vessels and is crucial
for the balance between CNS and periphery, maintained by
BBB. Physiological equilibrium of the intracerebral and the
bloodstream pools of Ab is due to specialized receptors
that allow a tightly regulated shuttle across BBB [6]. The
multiligand receptor RAGE, which binds also Ab/b-sheet
aggregates [34], dominate the influx at the BBB [21]. In
view of these evidences, RAGE has been found up-regu-
lated in human AD brains [35], has a pivotal role in brain
Ab deposition in AD experimental models [21], and has
been proposed as a fundamental mechanism signaling
danger to vulnerable vasculature [36]. Moreover, we
demonstrated that high blood pressure might interfere with
RAGE signaling inducing the AD pathology. On this issue,
we have exploited our murine model of hypertension–in-
duced AD-related pathology [31–37], to investigate the
role of RAGE. Interestingly, mice with genetic ablation of
RAGE, showed protection from hypertension-induced Ab
deposition and cognitive deterioration. [32]. Interestingly,
we obtained a similar protection when we used a recently
developed high-affinity tertiary amide RAGE-specific
inhibitor (FPS-ZM1), shown to block Ab binding specifi-
cally to the V-domain of RAGE [38], thus opening novel
therapeutic opportunities for vascular forms of AD.
6 Conclusions
Despite the established clinical link between hypertension
and AD, only a few basic science studies have investigated
the specific molecular relationship so far. In particular, while
most studies use engineered animal models that mimic
genetic AD, constituting only a small fraction of AD cases,
we pursued the strategy to exploit vascular related animal
models. On this issue, the possibility to manipulate vascular
risk factors, like hypertension, in mice, in order to investigate
the impact on brain pathology and cognitive deficits ascrib-
able to AD, appears as the best chance to allow investigators
to dissect the molecular mechanisms of spontaneous AD and
thus afford novel and targeted therapeutic strategies.
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